Hairy cell leukemia disease burden study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study watches the course of hairy cell leukemia (HCL) in different phases—when first diagnosed, after it comes back, or long after successful treatment. The goal is to better understand the disease and plan future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hairy cell leukemia (HCL) that has been confirmed by a biopsy.
- You are either newly diagnosed and about to start treatment, or you have had treatment before and the leukemia has come back, or you have been in complete remission for at least 5 years.
- You are 18 years old or older.
- You do not have another active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the best way to treat hairy cell leukemia and checks how well the approach works in people who need treatment for their disease. It may help if you have classic hairy cell leukemia and have not had certain prior chemotherapy.
This study asks adults with hairy cell leukemia to share their medical trial experiences and supports, through scheduled study visits and check-ins. It may help researchers understand what patients go through and what could be improved for future studies.
This early-stage (Phase 1) study tests a new type of treatment made from your T cells (immune cells) that are programmed to find and kill cancer cells with a specific marker (CD22). It’s designed for people with hairy cell leukemia that has come back or didn’t respond to prior treatments, and it aims to see safety and how well the approach works.
This trial tests whether a combination of two medicines—cladribine and rituximab—can treat hairy cell leukemia. You might be able to join if your leukemia is confirmed and you meet timing, blood test, and health requirements.
This trial tests a drug called binimetinib in people with a type of leukemia that has come back or not responded to treatment. It is for those whose cancer cells do not have a BRAF mutation.
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
Hear when a new Hairy Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.